CHANGES OF CEA, CYFRA21-1, CA125 AND PLATELET PARAMETERS IN PATIENTS WITH ADVANCED NSCLC BEFORE AND AFTER PLATINUM-BASED CHEMOTHERAPY

Liqiang Cao, Xiaowen Wang, Lan Wang, Lei Cao, Jun Tao, Jie Li, Chengying Liu^*

Department of Respiratory Medicine, Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, PR China

Objective: To study the changes in carcinoembryonic antigen (CEA), CYFRA21-1, CA125, and platelet parameters in patients with advanced non-small cell lung cancer (NSCLC) before and after platinum-based chemotherapy. 

Methods: A total of 60 patients with NSCLC treated in our hospital from July 2018 to July 2019 were recruited and divided into the control group (n=32) and observation group (n=28) according to the treatment regimen. The control group was given pemetrexed, and the observation group was treated with carboplatin based on pemetrexed. The treatment effect and adverse reactions of the patients in the two groups were observed; 5 ml of fasting venous blood was collected from all patients. The CEA, CYFRA21-1, and CA125 levels in all patients before and after treatment were measured by electrochemical luminescence immunoassay; 2 ml of fasting venous blood was collected from all patients before and after treatment, and the platelet count (PLT), mean platelet volume (MPV), platelet specific volume (PCT), and platelet distribution width (PDW) of all patients were measured using a fully automatic blood cell counter. 

Results: Before treatment, there was no significant difference between the serum CEA, CYFRA21-1, and CA125 levels of the patients in the two groups (P>0.05). After treatment, the levels of CEA, CYFRA21-1, and CA125 in the serum of the patients in both groups had decreased; the levels of CEA, CYFRA21-1, and CA125 in the serum of the observation group were significantly lower than those of the control group, and the difference was statistically significant (P<0.05). Before treatment, there was no significant difference between the serum PCT, PLT, MPV, and PDW levels of the patients in the two groups (P>0.05). After treatment, the levels of PCT, PLT, and MPV in the serum of the patients in the two groups had decreased; the levels of PCT, PLT, and MPV in the serum of the observation group were significantly higher than those of the control group, and the difference was statistically significant (P<0.05). There was no significant change in PDW level (P>0.05). The effective rate in the observation group was 75.00%, which was significantly higher than the 46.88% in the control group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 21.43%, which was significantly lower than the 53.13% in the control group, and the difference was statistically significant (P<0.05). 

Conclusion: Platinum-based chemotherapy can reduce the levels of CEA, CYFRA21-1, and CA125 in patients with NSCLC, but it has a lower effect on the levels of PCT, PLT, MPV, and PDW, reduces the incidence of thrombocytopenia, and has good efficacy and less adverse reactions, and can be widely used in clinics.